Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Cash from Financing Activities (2020 - 2025)

Oncology Institute (TOI) has disclosed Cash from Financing Activities for 6 consecutive years, with $10.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities rose 4462.14% year-over-year to $10.6 million, compared with a TTM value of $7.7 million through Sep 2025, up 249.91%, and an annual FY2024 reading of -$3.5 million, up 49.0% over the prior year.
  • Cash from Financing Activities was $10.6 million for Q3 2025 at Oncology Institute, up from $2.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $136.1 million in Q4 2021 and bottomed at -$10.7 million in Q2 2022.
  • Average Cash from Financing Activities over 5 years is $12.8 million, with a median of -$847000.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities plummeted 290609.68% in 2021, then skyrocketed 1317537.5% in 2022.
  • Year by year, Cash from Financing Activities stood at $136.1 million in 2021, then crashed by 100.62% to -$847000.0 in 2022, then crashed by 110.27% to -$1.8 million in 2023, then skyrocketed by 90.79% to -$164000.0 in 2024, then skyrocketed by 6563.41% to $10.6 million in 2025.
  • Business Quant data shows Cash from Financing Activities for TOI at $10.6 million in Q3 2025, $2.0 million in Q2 2025, and -$4.7 million in Q1 2025.